Children receiving intermediate, high dose MTX experience poor CINV control
the ONA take:
Children with cancer receiving methotrexate had a poor complete chemotherapy-induced nausea and vomiting (CINV) rate, both in the acute and delayed phases, according to a new study published in the journal Supportive Care in Cancer.
For the prospective study, 30 children received intermediate-dose (ID-MTX: >1 to <12/g/m2/dose) or high-dose methotrexate (HD-MTX: ≥12 g/m2/dose). CINV prophylaxis was provided to pediatric patients at the discretion of the clinician.
Researchers documented antiemetic administration, nausea severity, and emetic episodes during the acute phase (for 24 hours from the start of the methotrexate infusion) and the delayed phase (for up to a further 168 hours).
Researchers found that CINV prophylaxis received ondansetron or granisetron plus dexamethasone or nabilone. Results showed that among the 10 patients that received HD-MTX, 0% achieved complete control during the acute phase and 30% experienced complete control in the delayed phase.
Among the 20 patients that received ID-MTX, the complete control rates were 20% and 5% in the acute and delayed phase, respectively.
The findings confirm the classification of HD-MTX as highly emetogenic chemotherapy and suggest that ID-be reclassified as highly emetogenic chemotherapy, as well.
Children with cancer receiving methotrexate had a poor complete chemotherapy-induced nausea and vomiting (CINV) rate.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|